摘要
目的观察奈达铂联合多西紫杉醇方案治疗晚期食管癌的疗效和安全性。方法 43例晚期食管癌鳞癌初治患者,随机分为2组:Ned/Doc组,21例,奈达铂联合多西紫杉醇方案化疗;Cis/Doc组,22例,顺铂联合多西紫杉醇方案化疗,每3周1个疗程,总治疗不超过6个疗程。结果 2组患者客观缓解率(ORR)、临床获益率、进展时间(TTP)及平均生存时间比较,差异不具有统计学意义。2组患者大部分治疗相关性毒副反应是轻中度。治疗组3/4级毒性反应主要是中性粒细胞及血小板减少,对照组3/4级毒性反应主要是恶心、呕吐、神经毒性。结论在晚期食管癌中,奈达铂联合多西紫杉醇方案与顺铂联合多西紫杉醇方案疗效相近,但在毒副反应方面,奈达铂联合多西紫杉醇方案更具有优势。
Objective To observe the efficacy and safety of Nedaplatin combined with docetaxel in the treatment of advanced esophageal cancers.Methods 43 patients were enrolled.Amongst 22 patients undergoing Cis/Doc,21 patients undergoing Ned/Doc.Cis/Doc regimen included cisplatin 25 mg/m2 days1 to 3 and docetaxel 75 mg/m2 day1,while Ned/Doc comprised of nedaplatin 25 mg/m2 days1 to 3 and docetaxel 75 mg/m2 day1.Both regimens were administered intravenously every 21 days and no more than six cycles.Results There was not significantly difference between the both groups in ORR,CBR,TTP and MST.Most of the side effects was manageable.Gastrointestinal toxicity was mainly found in Cis/Doc group,while hematologic toxicity in Ned/Doc group.Conclusion Although they had similar efficacy,Ned/Doc may have an advantage over Cis/Doc with respect to side effcets.
出处
《实用临床医药杂志》
CAS
2011年第1期43-45,共3页
Journal of Clinical Medicine in Practice
关键词
晚期食管癌
奈达铂
多西紫杉醇
metastatic esophageal cancer
nedaplatin
docetaxel
